Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM060 in Diarrhea-predominant Irritable Bowel Syndrome
NCT00189813Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2005
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of ramosetron in Irritable bowel syndrome with diarrhea (IBS-D) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Global assessment of relief of IBS symptoms. Started Mar 2005; status: completed.
02
Drugs
ramosetron
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT00189813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189813.